14 Aug, EOD - Indian

Nifty 50 24631.3 (0.05)

SENSEX 80597.66 (0.07)

Nifty Bank 55341.85 (0.29)

Nifty Midcap 100 56504.25 (-0.31)

Nifty Pharma 22151.85 (0.10)

Nifty Next 50 66511.6 (-0.17)

Nifty IT 34833.2 (0.40)

Nifty Smallcap 100 17547.45 (-0.38)

14 Aug, EOD - Global

NIKKEI 225 43378.31 (1.71)

HANG SENG 25270.07 (-0.98)

S&P 6483.5 (-0.29)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(03 Jan 2024, 15:26)

Dr. Reddy's Lab acquires MenoLabs business from Amyris

The pharma major announced that it has acquired MenoLabs business, leading women’s health and dietary supplement branded portfolio from Amyris.


The Pharmaceuticals company has acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause.

Brands include MenoFit and MenoGlow probiotics, Happy Fiber and Well Rested dietary supplements, Athena’s Shield menopause support supplement, and Goodness Glow and Keep Glowing Gorgeous supplements for healthy aging support.

The deal also includes the MenoLife health tracker app which supports the product line and provides community, education, and information to consumers regarding menopause. MenoLabs portfolio of products is sold in the United States, primarily through the brand’s website and other e-commerce marketplaces including Amazon and Walmart.

Marc Kikuchi, chief executive officer for Dr. Reddy’s in North America, said, “The MenoLabs acquisition will serve as a catalyst to accelerate growth in this space and build upon our aspiration to lead in the fast-growing women’s nutritional and wellness markets.

The acquisition complements Dr. Reddy’s U.S. selfcare and wellness business portfolio of brands and addresses unmet needs of consumers for sciencebased, research-driven products that provide relief from the symptoms of menopause. For these and many other reasons, I believe we are well-positioned to successfully integrate and grow the business.”

Dr. Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.

The drug major's consolidated net profit increased 33% to Rs 1,480 crore on 9.11% rise in revenues to Rs 6,880.2 crore in Q2 FY24 over Q2 FY23.

The scrip rose 0.01% to Rs 5,925.50 on the BSE.

More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +